uniQure Sees Unusually Large Options Volume (NASDAQ:QURE)

uniQure (NASDAQ:QURE - Get Free Report) was the recipient of some unusual options trading on Tuesday. Investors bought 8,961 call options on the company. This is an increase of approximately 314% compared to the average daily volume of 2,162 call options.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Cantor Fitzgerald raised uniQure to a "strong-buy" rating in a research report on Monday, May 19th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of uniQure in a research note on Thursday, May 29th. Guggenheim reaffirmed a "buy" rating and set a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. Wall Street Zen upgraded shares of uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Wells Fargo & Company lowered their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Stock Down 1.3%

uniQure stock traded down $0.20 during midday trading on Wednesday, hitting $14.96. 770,949 shares of the company were exchanged, compared to its average volume of 1,904,913. The company's fifty day moving average price is $12.59 and its 200-day moving average price is $13.03. The company has a market cap of $819.45 million, a PE ratio of -3.02 and a beta of 0.10. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. On average, research analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock valued at $195,000 after acquiring an additional 969 shares during the last quarter. Tudor Investment Corp ET AL increased its holdings in uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 1,371 shares in the last quarter. Wells Fargo & Company MN increased its holdings in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 1,503 shares in the last quarter. Northern Trust Corp increased its stake in shares of uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after buying an additional 1,923 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of uniQure by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock valued at $1,253,000 after buying an additional 3,996 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.